AlphaMark Advisors LLC Has $44,000 Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Posted by Editorial Team on Jan 27th, 2025

AlphaMark Advisors LLC lifted its holdings in Aligos Therapeutics, Inc. (NASDAQ:ALGS – Free Report) by 1,000.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,100 shares of the company’s stock after acquiring an additional 1,000 shares during the quarter. AlphaMark Advisors LLC’s holdings in Aligos Therapeutics were worth $44,000 at the end of the most recent reporting period.

Aligos Therapeutics Trading Down 4.9 %

ALGS opened at $30.43 on Monday. Aligos Therapeutics, Inc. has a 1-year low of $6.76 and a 1-year high of $46.80. The firm has a 50-day moving average price of $32.24 and a two-hundred day moving average price of $18.86. The stock has a market capitalization of $109.18 million, a PE ratio of -2.28 and a beta of 2.50.

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($3.07) earnings per share for the quarter, missing the consensus estimate of ($2.15) by ($0.92). The company had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.00 million. Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. During the same quarter last year, the firm earned ($10.25) EPS. On average, research analysts predict that Aligos Therapeutics, Inc. will post -10.36 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

View Our Latest Research Report on Aligos Therapeutics

About Aligos Therapeutics

(Free Report)

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).